Advertisement

Molecular Medicine

, Volume 19, Issue 1, pp 109–114 | Cite as

Macrophage Migration Inhibitory Factor (MIF) and Thyroid Hormone Alterations in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

  • Mårten Wendt
  • Ola Börjesson
  • Aune Avik
  • Johan Bratt
  • Björn Anderstam
  • Abdul R. Qureshi
  • Edmund J. Miller
  • Iva Gunnarsson
  • Annette Bruchfeld
Research Article

Abstract

Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine known to be released from lymphocytes, macrophages and endothelial cells and also in animal models shown to be inducible with glucocorticoids (GC). In contrast, thyroxine seems to antagonize MIF activity. To investigate whether MIF is increased in active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and possible correlations with GC dosing and thyroid hormone levels, 27 consecutive patients with active AAV were studied and followed prospectively. Disease activity was assessed using Birmingham Vasculitis Activity Score 2003 (BVAS) at baseline and at follow-up at 3 and 6 months, along with MIF, thyroid hormones free triiodothyronine (fT3) and free thyroxine (fT4), C-reactive protein (CRP) and creatinine. MIF was elevated significantly at baseline compared with follow-up at 3 and 6 months (8,618 pg/mL versus 5,696 and 6,212 respectively; P < 0.002) but did not correlate to CRP GC dose, creatinine or organ involvement. fT3 was depressed significantly at baseline compared with follow-up (1.99 pg/mL versus 2.31 and 2.67 respectively; P = 0.01) and correlated inversely to the BVAS score at baseline. We found a significant correlation between the MIF/fT4 ratio at baseline versus MIF/fT4 ratio at 6 months (p = 0.52, P < 0.005) and a trend between the baseline MIF/fT3 ratio versus MIF/fT3 ratio at 6 months (ρ = 0.39, P = 0.05). These results suggest a possible role for MIF and thyroid status in AAV. Further studies could reveal whether the association between AAV and thyroid hormone levels in the context of elevated MIF may present a link as well as a target of treatment.

Notes

Acknowledgments

We thank the Fund for Renal Research, Karolinska Institutet Funds, the Swedish Society of Medicine, Westman Research Fund and King Gustaf V’s 80th Birthday Fund.

References

  1. 1.
    Jennette JC, et al. (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 37:187–92.CrossRefGoogle Scholar
  2. 2.
    Falk JR, Jennette JC. (2010) ANCA Disease: Where is this field heading? JASN. 21:74–52.CrossRefGoogle Scholar
  3. 3.
    Novak SN, Pearson CM. (1971): Cyclophosphamide therapy in Wegener’s granulomatosis. N. Engl. J. Med. 284:938–42.CrossRefGoogle Scholar
  4. 4.
    Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. (1992) The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 35:1322–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Stone JH, et al. (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363:221–32.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jones RB, et al. (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363:211–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Jayne D, et al. (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349:36–44.CrossRefPubMedGoogle Scholar
  8. 8.
    Grieb G, Merk M, Bernhagen J, Bucala J. (2010) Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect. 23:257–64.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Santos L, et al. (2011) Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis Rheum. 63:960–70.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Al-Abed Y, et al. (2011) Tyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity. PNAS. 108:8224–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Lehmann LE, et al. (2001) Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med. 27:1412–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Leech M, et al. (1999): Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum. 42:1601–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Foote A, et al. (2004) Macrophage migration inhibitory factor in systemic lupus erythematosus. J. Rheumatol. 31:268–73.PubMedGoogle Scholar
  14. 14.
    Kitaichi N, et al. (1999) Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest. Ophthalmol. Vis. Sci. 40:247–50.PubMedGoogle Scholar
  15. 15.
    Bruchfeld A, et al. (2009) Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. Mol. Med. 15:70–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang Y, et al. (2012) Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension. Mol. Med. 18:215–23.CrossRefPubMedGoogle Scholar
  17. 17.
    Zernecke A, Bernhagen J, Weber C (2008) Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 117:1594–602.CrossRefPubMedGoogle Scholar
  18. 18.
    Calandra T, et al. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 377:68–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Lionaki S, et al. (2007) Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol. Dial. Transplant. 22:3508–15.CrossRefPubMedGoogle Scholar
  20. 20.
    Luqmani RA, et al. (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 87:671–8.PubMedGoogle Scholar
  21. 21.
    Exley AR, et al. (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 40:371–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Levey AS, et al. (2006) Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145:247–54.CrossRefPubMedGoogle Scholar
  23. 23.
    Ohwatari R, et al. (2001) Serum levels of macrophage migration inhibitory factor as a useful parameter of clinical coarse in patients with Wegener’s granulomatosis and relapsing polychondritis. Ann. Otol. Rhinol. Laryngol. 110:1035–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Becker H, et al. (2006) Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides. Clin. Rheumatol. 25:368–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Bozza M, et al. (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189:341–6.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Greven D, Leng L and Bucala R (2010) Autoimmune diseases: MIF as a therapeutic target. Expert Opin. Ther. Targets. 14:253–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Tam FW, et al. (2011) Fully human anti-macrophage migration inhibitory factor (MIF) antibody is effective in treatment of established experimental glomerulonephritis [Abstract]. J. Am. Soc. Nephrol. 22:134A.Google Scholar
  28. 28.
    Slot MC, Links TP, Stegeman CA, Tervaert JW. (2005) Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term follow-up study. Arthritis Rheum. 53:108–13.CrossRefPubMedGoogle Scholar
  29. 29.
    Umpierrez GE. (2002) Euthyroid sick syndrome. South Med. J. 95:506–13.CrossRefPubMedGoogle Scholar
  30. 30.
    Gao H, et al. (2011) Subclinical hypothyroidism and its association with lupus nephritis. A case control study in a large cohort of Chinese systemic lupus erythematosus patients. Lupus. 20:1035–41.CrossRefPubMedGoogle Scholar
  31. 31.
    Mebis L, Van den Berghe G (2011) Thyroid axis function and dysfunction in critical illness. Best Pract. Res. Clin. Endocrinol. Metab. 25:745–57.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2013

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Mårten Wendt
    • 1
  • Ola Börjesson
    • 2
  • Aune Avik
    • 2
  • Johan Bratt
    • 2
  • Björn Anderstam
    • 1
  • Abdul R. Qureshi
    • 3
  • Edmund J. Miller
    • 4
    • 5
  • Iva Gunnarsson
    • 2
  • Annette Bruchfeld
    • 1
  1. 1.Department of Renal Medicine, Karolinska University Hospital, Department of Clinical Sciences, Intervention and TechnologyKarolinska InstituteStockholmSweden
  2. 2.Unit of Rheumatology, Department of MedicineKarolinska University Hospital, Karolinska InstituteStockholmSweden
  3. 3.Baxter Novum, Department of Clinical Sciences, Intervention and TechnologyKarolinska InstituteStockholmSweden
  4. 4.Feinstein Institute for Medical ResearchManhassetUSA
  5. 5.Hofstra University School of MedicineHempsteadUSA

Personalised recommendations